Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2011-01-11
2011-01-11
Gussow, Anne M. (Department: 1643)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C530S387100
Reexamination Certificate
active
07867734
ABSTRACT:
An anti-glypican 3 antibody with modified sugar chains, more specifically, an anti-glypican 3 antibody lacking fucose is provided. The anti-glypican 3 antibody with modified sugar chains of the present invention may be produced by a process comprising introducing a nucleic acid encoding an anti-glypican 3 antibody into host cells with reduced fucose addition capability, such as YB2/0 cells and cells lacking a fucose transporter. The anti-glypican 3 antibody with modified sugar chains of the present invention has a high level of cytotoxic activity and therefore is useful as a cell growth inhibitor such as an anticancer agent.
REFERENCES:
patent: 5530101 (1996-06-01), Queen et al.
patent: 6165745 (2000-12-01), Ward et al.
patent: 6210670 (2001-04-01), Berg
patent: 6737056 (2004-05-01), Presta
patent: 7297775 (2007-11-01), Idusogie et al.
patent: 7361336 (2008-04-01), Bergstein
patent: 7427400 (2008-09-01), Bergstein
patent: 2004/0024320 (2004-02-01), Karasawa et al.
patent: 2004/0236080 (2004-11-01), Aburatani et al.
patent: 2005/0171339 (2005-08-01), Sugo et al.
patent: 2005/0233392 (2005-10-01), Filmus et al.
patent: 2006/0024298 (2006-02-01), Lazar et al.
patent: 2006/0040325 (2006-02-01), Wu et al.
patent: 2006/0167232 (2006-07-01), Aburatani et al.
patent: 2006/0188510 (2006-08-01), Aburatani et al.
patent: 2006/0287508 (2006-12-01), Sugo et al.
patent: 2007/0087005 (2007-04-01), Lazar et al.
patent: 2007/0172488 (2007-07-01), Aburatani et al.
patent: 2007/0190599 (2007-08-01), Nakano et al.
patent: 2007/0269444 (2007-11-01), Kinoshita et al.
patent: 2008/0008710 (2008-01-01), Aburatani et al.
patent: 2008/0051563 (2008-02-01), Lazar et al.
patent: 2008/0154025 (2008-06-01), Lazar et al.
patent: 2008/0161541 (2008-07-01), Lazar et al.
patent: 2008/0181890 (2008-07-01), Lazar et al.
patent: 2008/0267979 (2008-10-01), Lazar et al.
patent: 2003261941 (2004-03-01), None
patent: 1176195 (2002-01-01), None
patent: 1411118 (2002-06-01), None
patent: 1331266 (2003-07-01), None
patent: 1462799 (2004-09-01), None
patent: 1 464 702 (2004-10-01), None
patent: 1 498 491 (2005-01-01), None
patent: 1 541 680 (2005-06-01), None
patent: 1548442 (2005-06-01), None
patent: 1561686 (2005-08-01), None
patent: 1 671 645 (2006-06-01), None
patent: 1 674 111 (2006-06-01), None
patent: 1 800 693 (2007-06-01), None
patent: 1 816 140 (2007-08-01), None
patent: 2-42355 (1990-02-01), None
patent: 4-336051 (1992-11-01), None
patent: 11-118775 (1999-04-01), None
patent: 2001-108661 (2001-04-01), None
patent: 2002-48867 (2002-02-01), None
patent: 2003-149213 (2003-05-01), None
patent: 2004-053360 (2004-02-01), None
patent: 9322332 (1993-11-01), None
patent: 9823289 (1998-06-01), None
patent: WO 99/54342 (1999-10-01), None
patent: WO 00/61739 (2000-10-01), None
patent: WO 02/22739 (2002-03-01), None
patent: WO 02/31140 (2002-04-01), None
patent: WO 02/079255 (2002-10-01), None
patent: WO 03/000883 (2003-01-01), None
patent: WO 03/042686 (2003-05-01), None
patent: WO 03/057881 (2003-07-01), None
patent: WO 03/074679 (2003-09-01), None
patent: WO 03/085119 (2003-10-01), None
patent: WO 03/100429 (2003-12-01), None
patent: WO 2004/018667 (2004-03-01), None
patent: WO 2004/022597 (2004-03-01), None
patent: WO 2004/022739 (2004-03-01), None
patent: WO 2004/022754 (2004-03-01), None
patent: WO 2004/023145 (2004-03-01), None
patent: WO 2004/038420 (2004-05-01), None
patent: WO 2004/099249 (2004-11-01), None
patent: WO 2005/023301 (2005-03-01), None
patent: WO 2006/006693 (2006-01-01), None
patent: WO 2006/022407 (2006-03-01), None
patent: WO 2006/046751 (2006-05-01), None
patent: WO 2007/047291 (2007-04-01), None
Yamane-Ohnuki, Kinoshita, Inoue-Urakubo, Kusunoki, Iida, Nakano, Wakitani, Niwa, Sakurada, Uchida, Shitara, Satoh. Establishment of FUT8 knockout CHO cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnology and Bioengineering, 2004. vol. 87, pp. 614-622.
Rudikoff, Giusti, Cook and Scharff. Single amino acid substitution altering antigen-binding specificity. Proceedings of the National Academy of Sciences, 1982. vol. 79, pp. 1979-1983.
Casset, Roux, Mouchet, Bes, Chardes, Granier, Mani, Pugniere, Laune, Pau, Kaczorek, Lahana, and Rees. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochemical and Biophysical Research Communications, 2003. vol. 307, pp. 198-205.
Burgess, Shaheen, Ravera, Jaye, Donohue, and Winkles. Possible dissociation of the heparin binding and mitogenic activities of heparin binding (acidic fibroblast) growth factor 1 from its receptor binding activities by site directed mutagenesis of a single lysine residue. Journal of Cell Biology, 1990. vol. 111, pp. 2129-2138.
Lazar, Watanabe, Dalton, and Sporn. Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities. Molecular and Cellular Biology, 1988. vol. 8, pp. 1247-1252.
Abe et al., “Matrixeye™ Portable 3D Ultrasonic Inspection System,”Toshiba Review, 60:48-51, English abstract (2005).
Bendayan, “Possibilities of False Immunocytochemical Results Generated by the Use of Monoclonal Antibodies: the Example of the Anti-Proinsulin Antibody,”J. Histochem. Cytochem., 43:881-886 (1995).
Bost et al., “Antibodies Against a Peptide Sequence within the HIV Envelope Protein Crossreacts with Human Interleukin-2,”Immunol. Invest., 17:577-586 (1988).
Brorson et al., “Mutational Analysis of Avidity and Fine Specificity of Anti-Levan Antibodies,”J. Immunol., 163:6694-6701 (1999).
Brummell et al., “Probing the combining site of an anti-carbohydrate antibody by saturation-mutagenesis: role of the heavy-chain CDR3 residues,”Biochemistry, 32:1180-87 (1993).
Burks et al., “In vitro scanning saturation mutagenesis of an antibody binding pocket,”Proc. Natl. Acad. Sci. USA, 94:412-417 (1997).
Capurro et al., “Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma,”Gastroenterology, 125:89-97 (2003).
Capurro et al., “Overexpression of Glypican-3 in Human Hepatocellular Carcinomas Determined by Immunohistochemistry Using a Monocolonal Antibody,”Proceedings of the Annual Meeting of the American Association for Cancer Research, 93rdAnnual Meeting, Apr. 6-10, 2002, 43:219 Abstract #1097 (2002).
Carter, “Improving the efficacy of antibody-based cancer therapies,”Nat. Rev. Cancer, 1:118-129 (2001).
Casset et al., “A peptide mimetic of an anti-CD4 monoclonal antibody by rational design,”Biochem. Biophys. Res. Commun., 307:198-205 (2003).
Chen et al., “Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-Matured Fab in Complex with Antigen,”J. Mol. Biol., 293:865-881 (1999).
Colman, “Effects of amino acid sequence changes on antibody-antigen interactions,”Res. Immunol., 145:33-36 (1994).
De Pascalis et al., “Grafting of “Abbreviated” Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody,”J. Immunol., 169:3076-84 (2002).
Dennis, “Cancer: Off by a whisker,”Nature, 442:739-741 (2006).
Dufner et al., “Harnessing phage and ribosome display for antibody optimization,”Trends Biotechnol., 24:523-529 (2006).
Filmus, “Glypicans in Growth Control and Cancer,”Glycobiology, 11:19R-23R (2001).
Gonzalez et al., “OCI-5/GPC3, a Glypican Encoded by a Gene That is Mutated in the Simpson-Golabi-Behmel Overgrowth Syndrome, Induces Apoptosis in a Cell Line-Specific Manner,”J. Cell Biol., 141:1407-14 (1998).
Gura, “Systems for Identifying New Drugs Are Often Faulty,”Science, 278:1041-42 (1997).
Hippo et al., “Identification of Soluble NH2-Terminal Fragment of Glypican-3 as a Serological Marker for Early-Stage Hepatocellular Carcinoma,”Cancer Res., 64:2418-2
Iijima Shigeyuki
Ishiguro Takahiro
Nakano Kiyotaka
Sugimoto Masamichi
Sugo Izumi
Chugai Seiyaku Kabushiki Kaisha
Fish & Richardson P.C.
Gussow Anne M.
LandOfFree
Anti-glypican 3 antibody having modified sugar chain does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-glypican 3 antibody having modified sugar chain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-glypican 3 antibody having modified sugar chain will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2734035